Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2021 Sep 30

PMID 34590137

Citations 13

Authors

Gail L Rodgers

Cynthia G Whitney

Keith P Klugman

Affiliations

Soon will be listed here.

Abstract

Pneumococcal conjugate vaccine (PCV) has reduced the burden of pneumococcal disease by the near elimination of vaccine serotypes from countries giving a booster dose at >9 months of life. Herd protection, induced by interruption of pneumococcal vaccine type transmission has protected children too young to be immunized, children and adults with underlying risk conditions for invasive pneumococcal disease, and the elderly. PCV has rolled out in most poor countries, but millions of children remain un-immunized especially in middle income countries because of cost constraints. These are being met by considering fewer doses to maintain herd protection, and support for more affordable vaccine from developing country manufacturers. While 3rd generation PCV's with potential inclusion of 20+ serotypes are close to market in adults, it will be their introduction into childhood immunization and herd protection that is most likely to maximize the public health benefits of these vaccines.

Citing Articles

serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?.

Dhawale P, Shah S, Sharma K, Sikriwal D, Kumar V, Bhagawati A Hum Vaccin Immunother. 2025; 21(1):2461844.

PMID: 39999432 PMC: 11864319. DOI: 10.1080/21645515.2025.2461844.

Outbreak of Serotype 1 Invasive Pneumococcal Disease, Kibera Urban Informal Settlement, Nairobi, Kenya, 2023.

Komo T, Munywoki P, Carvalho M, Auko J, Ouma A, Audi A Emerg Infect Dis. 2025; 31(2):345-349.

PMID: 39983706 PMC: 11845131. DOI: 10.3201/eid3102.241652.

Nasopharyngeal carriage of Streptococcus pneumoniae among children and their household members in southern Mozambique five years after PCV10 introduction.

Kahn R, Moiane B, Lessa F, Massora S, Mabombo V, Chauque A Vaccine. 2025; 47:126691.

PMID: 39787794 PMC: 11797556. DOI: 10.1016/j.vaccine.2024.126691.

Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia, Spain (COVAIR-CAT).

Tonne C, Ranzani O, Alari A, Ballester J, Basagana X, Chaccour C Res Rep Health Eff Inst. 2024; (220):1-48.

PMID: 39468856 PMC: 11525941.

Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia.

von Mollendorf C, Mungun T, Ulziibayar M, Skoko P, Boelsen L, Nguyen C Nat Commun. 2024; 15(1):6577.

PMID: 39097620 PMC: 11297977. DOI: 10.1038/s41467-024-50944-3.

References

Tregnaghi M, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A . Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med. 2014; 11(6):e1001657. PMC: 4043495. DOI: 10.1371/journal.pmed.1001657. View

Bonten M, Huijts S, Bolkenbaas M, Webber C, Patterson S, Gault S . Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372(12):1114-25. DOI: 10.1056/NEJMoa1408544. View

Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen J . Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000; 19(3):187-95. DOI: 10.1097/00006454-200003000-00003. View

Madhi S, Klugman K . A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004; 10(8):811-3. PMC: 7095883. DOI: 10.1038/nm1077. View

Austrian R, Douglas R, Schiffman G, Coetzee A, Koornhof H, HAYDEN-SMITH S . Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians. 1976; 89:184-94. View

Klugman K, Madhi S, Huebner R, Kohberger R, Mbelle N, Pierce N . A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003; 349(14):1341-8. DOI: 10.1056/NEJMoa035060. View

Hammitt L, Etyang A, Morpeth S, Ojal J, Mutuku A, Mturi N . Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet. 2019; 393(10186):2146-2154. PMC: 6548991. DOI: 10.1016/S0140-6736(18)33005-8. View

von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C . Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014; 371(20):1889-99. DOI: 10.1056/NEJMoa1401914. View

Palmu A, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L . Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2012; 381(9862):214-22. DOI: 10.1016/S0140-6736(12)61854-6. View

10.

Palmu A, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T . Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis. 2013; 14(3):205-12. DOI: 10.1016/S1473-3099(13)70338-4. View

11.

Griffin M, Zhu Y, Moore M, Whitney C, Grijalva C . U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013; 369(2):155-63. PMC: 4877190. DOI: 10.1056/NEJMoa1209165. View

12.

Cutts F, Zaman S, Enwere G, Jaffar S, Levine O, Okoko J . Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005; 365(9465):1139-46. DOI: 10.1016/S0140-6736(05)71876-6. View

13.

Simonsen L, Taylor R, Young-Xu Y, Haber M, May L, Klugman K . Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio. 2011; 2(1):e00309-10. PMC: 3025524. DOI: 10.1128/mBio.00309-10. View

14.

Whitney C, Farley M, Hadler J, Harrison L, Bennett N, Lynfield R . Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003; 348(18):1737-46. DOI: 10.1056/NEJMoa022823. View